Business meeting to consider S.1425, to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, S.1428, to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products, S.1388, to require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, S.1435, to amend the Federal Trade Commission Act to prohibit product hopping, and the nominations of Myrna Perez, of New York, to be United States Circuit Judge for the Second Circuit, Jia M. Cobb, of Virginia, and Florence Y. Pan, both to be a United States District Judge for the District of Columbia, Sarah A.L. Merriam, to be United States District Judge for the District of Connecticut, Karen McGlashan Williams, to be United States District Judge for the District of New Jersey, and Matthew G. Olsen, of Maryland, to be an Assistant Attorney General, Department of Justice.